Lyra Therapeutics Suspends Development of LYR-210 Amid Strategic Shift
WATERTOWN, Mass., January 12, 2026 (GLOBE NEWSWIRE) — Lyra Therapeutics, Inc. (Nasdaq: LYRA) has announced a significant corporate update regarding its future plans.
Decision to Halt LYR-210 Development
On January 12, 2026, Lyra Therapeutics revealed that its Board of Directors has decided to suspend further development of LYR-210, the company’s primary candidate for treating chronic rhinosinusitis (CRS). This decision is accompanied by a workforce reduction affecting its remaining 28 employees, which is part of broader cost-saving measures aimed at preserving capital.
Dr. Maria Palasis, Chief Executive Officer and Chair of the Board, stated, “In connection with the Company’s review of strategic options, which was announced in May 2024, the Board has concluded that it is in the best interests of shareholders to cease Lyra’s product development operations.”
Workforce Reductions and Strategic Alternatives
As part of this transition, both Dr. Palasis and Chief Financial Officer Jason Cavalier will continue to serve as consultants. They're tasked with aiding the Company in pursuing strategic alternatives. Additionally, Lyra has engaged SSG Capital Advisors, LLC to assist in this strategic exploration.
Dr. Palasis expressed gratitude for the contributions of the employees who will be departing, emphasizing the company's commitment to evaluating ways to advance LYR-210 for the potential benefit of patients.
Financial Overview and Future Outlook
As of September 30, 2025, Lyra Therapeutics reported approximately $22.1 million in cash, cash equivalents, and short-term investments. The Company anticipates that its cash runway will last into the third quarter of 2026.
However, the future remains uncertain as Lyra has not set a definitive timeline for its strategic efforts and does not plan to provide regular updates on its status. The Company warns that there can be no assurance that any strategic alternatives pursued will lead to successful transactions.
Recent Clinical Developments for LYR-210
In June 2025, Lyra Therapeutics reported positive results from the ENLIGHTEN 2 Phase 3 trial of LYR-210, achieving statistically significant outcomes for both primary and key secondary endpoints in CRS patients without nasal polyps. With an estimated three million U.S. patients suffering from non-polyp CRS annually, LYR-210 targets a critical healthcare need.
Lyra has developed an upcoming clinical strategy that includes an additional Phase 3 trial, which is planned in collaboration with the U.S. Food and Drug Administration (FDA) to support a new drug application (NDA) for LYR-210.
Forward-Looking Statements and Caution
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Important factors influencing these statements include risks related to the development process, funding requirements, and the ongoing viability of Lyra as a public company.
Lyra cautions that there is no guarantee of future performance, and actual results may differ materially from projections made in this report due to various known and unknown risks.